Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Wan Teck Lim, Maria Q. Baggstrom, William Read, Paula M. Fracasso & Ramaswamy Govindan. (2008) A Phase I trial of weekly docetaxel and topotecan for solid tumors. Acta Oncologica 47:2, pages 311-315.
Read now
Read now
Banu Arun & Eugene P Frenkel. (2001) Topoisomerase I inhibition with topotecan: pharmacologic and clinical issues. Expert Opinion on Pharmacotherapy 2:3, pages 491-505.
Read now
Read now
Articles from other publishers (21)
Justine L. DelgadoChao-Ming Hsieh, Nei-Li Chan & Hiroshi Hiasa. (2018) Topoisomerases as anticancer targets. Biochemical Journal 475:2, pages 373-398.
Crossref
Crossref
Imran Masood, Maria H. Kiani, Mahmood Ahmad, Muhammed I. Masood & Hadia Sadaquat. (2015) Major Contributions towards Finding a Cure for Cancer through Chemotherapy: A Historical Review. Tumori Journal 102:1, pages 6-17.
Crossref
Crossref
S. Agelaki, E. Kontopodis, A. Kotsakis, V. Chandrinos, I. Bompolaki, Ζ. Zafeiriou, E. Papadimitraki, D. Stoltidis, K. Kalbakis & V. Georgoulias. (2013) A phase I clinical trial of weekly oral topotecan for relapsed small cell lung cancer. Cancer Chemotherapy and Pharmacology 72:1, pages 45-51.
Crossref
Crossref
Vincent J. Venditto & Eric E. Simanek. (2010)
Cancer Therapies Utilizing the Camptothecins: A Review of the
in Vivo
Literature
. Molecular Pharmaceutics 7:2, pages 307-349.
Crossref
Crossref
William N. William, Joseph L. Lee, Dong M. Shin, Waun K. Hong, Suyu Liu, J Jack Lee, Scott M. Lippman, Fadlo R. Khuri & Edward S. Kim. (2009) Phase I Trial of Weekly Topotecan and Gemcitabine in Patients With Solid Tumors. American Journal of Clinical Oncology 32:1, pages 15-19.
Crossref
Crossref
Sabine Wagner, Ove Peters, Christin Fels, Gisela Janssen, Anne-Kathrin Liebeskind, Axel Sauerbrey, Meinolf Suttorp, Peter Hau & Johannes E. A. Wolff. (2007) Pegylated-liposomal doxorubicin and oral topotecan in eight children with relapsed high-grade malignant brain tumors. Journal of Neuro-Oncology 86:2, pages 175-181.
Crossref
Crossref
Eric Scholar. 2007. xPharm: The Comprehensive Pharmacology Reference. xPharm: The Comprehensive Pharmacology Reference
1
5
.
David M. O'Malley, Masoud Azodi, Anita Makkenchery, Jacob Tangir, Jessica McAlpine, Michael Kelly, Peter Schwartz & Thomas Rutherford. (2005) Weekly topotecan in heavily pretreated patients with recurrent epithelial ovarian carcinoma. Gynecologic Oncology 98:2, pages 242-248.
Crossref
Crossref
John R. Eckardt. (2004) Emerging Role of Weekly Topotecan in Recurrent Small Cell Lung Cancer. The Oncologist 9:S6, pages 25-32.
Crossref
Crossref
Snehal M. Bhoola, Robert L. Coleman, Thomas Herzog, Robert Morris, Christopher Bryant, Jacob M. Estes & Ronald D. Alvarez. (2004) Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer. Gynecologic Oncology 95:3, pages 564-569.
Crossref
Crossref
Sabine Wagner, Bernhard Erdlenbruch, Alfred Längler, Astrid Gnekow, Joachim Kühl, Michael Albani, Sigrid Völpel, Peter Bucsky, Angela Emser, Ove Peters & Johannes E. A. Wolff. (2004) Oral topotecan in children with recurrent or progressive high‐grade glioma. Cancer 100:8, pages 1750-1757.
Crossref
Crossref
Najat C. DawVictor M. SantanaLisa C. IaconoWayne L. FurmanDana R. HawkinsPeter J. HoughtonJ. Carl PanettaAmar J. GajjarClinton F. Stewart. (2004) Phase I and Pharmacokinetic Study of Topotecan Administered Orally Once Daily for 5 Days for 2 Consecutive Weeks to Pediatric Patients With Refractory Solid Tumors. Journal of Clinical Oncology 22:5, pages 829-837.
Crossref
Crossref
Joseph Treat. (2003) Weekly topotecan in the management of lung cancer. Lung Cancer 41, pages S27-S31.
Crossref
Crossref
Robert Morris & Adnan Munkarah. (2002) Alternate Dosing Schedules for Topotecan in the Treatment of Recurrent Ovarian Cancer. The Oncologist 7:S5, pages 29-35.
Crossref
Crossref
Wayne L. FurmanClinton F. StewartMark KirsteinJames L. KepnerMark L. BernsteinFaith KungTeresa J. ViettiC. Philip SteuberDavid Lee BectonSylvain BaruchelCharles Pratt. (2002) Protracted Intermittent Schedule of Topotecan in Children With Refractory Acute Leukemia: A Pediatric Oncology Group Study. Journal of Clinical Oncology 20:6, pages 1617-1624.
Crossref
Crossref
M De Cesare, F Zunino, S Pace, C Pisano & G Pratesi. (2000) Efficacy and toxicity profile of oral topotecan in a panel of human tumour xenografts. European Journal of Cancer 36:12, pages 1558-1564.
Crossref
Crossref
Franz von Bruchhausen, Siegfried Ebel, Eberhard Hackenthal, Ulrike Holzgrabe, Margitta Albinus, Gudrun Amschler, Erwin von Angerer, C. Arras-Reiter, Andrea Bauer, Pia Bauer, Winfried Beil, Thorsten Beyrich, Katja Binder, Roswitha Böhme, Hans-Hubertus Borchert, Franz Bossle, Franz Bracher, Helmut Bräunlich, Ellen Bretschneider, Regina Brigelius-Flohé, Kerstin Brinkmann, Axel Büge, Wolfram Christ, Monika Cimbollek, Rolf Daniels, Gerd Dannhardt, Hans-Jürgen Duchstein, Kurt Eger, Petra Eichhorn, Michael Engler, Thomas Erker, Peter Felfe, Alfred Fenyves, Reinhard Fescharek, Carmen Frackenpohl, August Wilhelm Frahm, Margarete Frahm, Volker Franke, Ulrich Franken, Detlef Geffken, Uli Geis, Erika Glusa, Berthold Göber, Peter Ndive Gobina, Werner Golder, Margarete Goppelt-Strübe, Katharina Götte, Erkme Gottstein, Michael Grosam, Markus von Gruchalla, Michael Gütschow, Annette Häfner, Boris Haluszczynski, Achim Harder, Sabine Hartmann, Susanne Hartmann, Dieter Heber, Gerhard Heinemeyer, Eberhard Heller, Dietrich von Herrath, J. Hilfenhaus, Ute Hoffmann-Schollmayer, Bernhard Hofmann, Christian Holpert, Ute Hübner-Steiner, Elisabeth Inkmann, Jens Jürgens, Brigitte Kaiser, Dieter-Abbo Kalbhen, Hans Kemmler, Werner Kiefer, Christoph Klett, Stephanie Klett, Martin Klingmüller, Hans-Peter Klöcking, Gerd Kobal, Axel Kramer, Mareta Kreher, M. Krüger, Markus Kuhn, Marion Sylvia Lehner, Detlef Leopoldt, Georg Liedtke, Detlef Manns, Wolfgang Matthiessen, Andreas Maurer, Wolfgang Meindl, Klaus Menges, Paul Messinger, Frank Peter Meyer, Wolfgang Meyerhof, Manfred Moos, Rudolf Morgenstern, Klaus Müller, Walter E. Müller, Corina Nachtsheim, Tilo Netzer, Michael Neugebauer, Werner Neupert, Peter Nickel, Peter Nuhn, Bernd Nürnberg, H. Oelschläger, Joachim Oertel, Michael Oettel, Hartmut Oßwald, Robert Ott, Tilmann Ott, Thomas Otzen, Peter Pachaly, Helmut Pelzer, Karl-Uwe Petersen, Rainer Pick, Martina Pickert, Andreas Pies, Eberhard Reimann, Joachim Richter, Kai Riecke, Suzanne Ritter, Hans Rommelspacher, Ulrich Rose, Gernot Roth, Gerhard Rücker, Judith Schäfer, Joachim G. Schantl, Helmut Schlager, Hildegard Schleinitz, Max Schmauß, Helmut Schmidhammer, Gerhard Schmidt, Timo Schmidt, B. Schneeweiß, Johannes Schräder, Thomas Schulz, Gert Schulze, Peter Schwanz, Johannes Schweiger, Gisela Skopp, Gisela Skorka, Kai Smolinka, Ulrich Speck, Ralf Stahlmann, Herbert Stein, Karlheinz Stiefvater, Karl-Heinz Surborg, Ulf Sürig, Hubert Szelényi, Istvan Szelenyi, Alfred Täufel, Ruth Thieroff-Ekerdt, Reinhard Troschütz, Michael Verborg, Eugen J. Verspohl, Sabine Vogel, Franz-Josef Volk, Thomas Vorwerk, Jürgen Wallmann, Martin Wenzel, Marion Weyandt-Spangenberg, Sandra Wich, Reinhold Wintersteiger, Frauke Woltmann, Beate Wüst, G. Zilow & A. Kluge. 1999. Hagers Handbuch der Pharmazeutischen Praxis. Hagers Handbuch der Pharmazeutischen Praxis
607
701
.
Joyce Thompson, Clinton F. Stewart & Peter J. Houghton. (1998) Animal models for studying the action of topoisomerase I targeted drugs. Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression 1400:1-3, pages 301-319.
Crossref
Crossref
Lalitha Iyer & Mark J. Ratain. (1998) Clinical pharmacology of camptothecins. Cancer Chemotherapy and Pharmacology 42:S1, pages S31-S43.
Crossref
Crossref
G. Vassal, C. Pondarré, I. Boland, C. Cappelli, A. Santos, C. Thomas, E. Lucchi, K. Imadalou, F. Pein, J. Morizet & A. Gouyette. (1998) Preclinical development of camptothecin derivatives and clinical trials in pediatric oncology. Biochimie 80:3, pages 271-280.
Crossref
Crossref
FRANCO M. MUGGIA, ISAIAH DIMERY & SUSAN G. ARBUCK. (1996) Camptothecin and Its Analogs.. Annals of the New York Academy of Sciences 803:1 The Camptothe, pages 213-223.
Crossref
Crossref